ABSTRACT
PURPOSE: Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2). METHODS: We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA). RESULTS: More than half of the patients could go on with venetoclax for only a few months. CONCLUSION: Using venetoclax combined with HMA in R/R AML should be kept in mind as an alternative salvage option.
Subject(s)
Antineoplastic Agents/therapeutic use , Azacitidine/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Decitabine/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Methyltransferases/antagonists & inhibitors , Neoplasm Recurrence, Local/drug therapy , Sulfonamides/therapeutic use , Adult , Drug Combinations , Female , Humans , Male , Middle Aged , Young AdultABSTRACT
PURPOSE: Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. METHODS: The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. RESULTS: The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most patients were diagnosed with disease at an advanced stage. Pralatrexate therapy was given to the patients at a median treatment line of 3.5. Pralatrexate dose reduction was required in only 3 patients (15%). Response to pralatrexate therapy with partial remission (PR) and above was observed in 11 (55%) of the patients. CONCLUSION: Pralatrexate seemed to be a promising novel treatment in relapsed refractory PTCL patients. However, patients receiving pralatrexate should be followed up carefully for skin reactions, mucosal side effects, thrombocytopenia and neutropenia.
Subject(s)
Aminopterin/analogs & derivatives , Lymphoma, T-Cell, Peripheral/drug therapy , Aminopterin/therapeutic use , Female , Humans , Male , Middle Aged , Retrospective Studies , Treatment Outcome , TurkeyABSTRACT
BACKGROUND: Extramedullary plasmacytoma of the skin, a rare type of cutaneous B-cell lymphoma, is characterized by clonal proliferation of plasma cells primarily in the skin without evidence of multiple myeloma. Only about 30 cases with extramedullary plasmacytoma of the skin are reported in the literature. CASE REPORT: An 82-year-old male patient presented to our clinic with complaints of asymptomatic red nodular swelling and pain in the anterior chest wall. A dermatologic examination revealed multiple nodular lesions of varying sizes with a hard smooth surface and vivid red color. Serum protein and immunoglobulin electrophoresis, skeletal radiography, and bone marrow biopsy showed normal results in this patient. Here a rare case of multiple primary plasmacytoma localizing in the skin is reported.
Subject(s)
Neoplasms, Multiple Primary/diagnosis , Plasmacytoma/diagnosis , Skin Neoplasms/diagnosis , Aged, 80 and over , Humans , Immunohistochemistry , Male , Neoplasms, Multiple Primary/pathology , Plasmacytoma/pathology , Skin Neoplasms/pathologyABSTRACT
AIM: To evaluate the characteristics of patients with hepatitis B virus (HBV) infection and summarize the treatment modalities. METHODS: By September 30, 2011 the data of 7871 HBsAg (+) patients were complied and analysed according to demographic and medical records (age, sex, laboratory tests, treatment with antiviral agents) in thirty centres of Turkey. RESULTS: Of the 7871 patients 3078 (39.1%) were females; mean (standard deviation) age was 35 (14) years, 3180 (40.4%) were HBsAg positive (+) after admission to a hospital, 1488 (18.9%) after blood donation and 967 (11.9%) were found during routine screening. The HBV prevalence among relatives of HBsAg (+) patients was 1764 (22.4%), and most frequently infected family members were siblings and mothers, 4961 (63.0%) and 2149 (27.3%), respectively). Anti-HDV was negative in 7407 94.1% of patients. Three-fourths of the patients 6383 (81.1%) were HBeAg negative (-). Mean (SD) ALT was 85.8 (266.4) U/L. Majority of patients, 5588 (71.0%) were chronic hepatitis-B patients under treatment, while 2283 (29.0%) were asymptomatic carriers without treatment and only 165 (2.1%) of patients were cirrhotic and 6612 (84.0%) of those were compensated. One-third of the patients 2983 (37.9%) were under a combined treatment, while others were under monotherapy. Lamivudine, entecavir and adefovir were the most frequently used oral therapies, used for 2583 (32.8%), 11.6% and 787 (10.0%) of patients, respectively), while 2975 (37.8%) of patients were under interferon treatment. CONCLUSION: Hepatitis B is still a problem in our country. First task of the physicians and our state should be to prevent the development and spread of the disease with education and vaccination programs, safe blood transfusions, and control of barbers.
